Thelansis

Multiple Myeloma Market Outlook Thelansis’s “Multiple Myeloma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple Myeloma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights...

Multiple Myeloma Market Outlook Thelansis’s “Multiple Myeloma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple Myeloma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Multiple Myeloma Overview Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of clonal plasma cells in the bone marrow, which secrete significant quantities of non-functional proteins and immunoglobulins. Despite notable therapeutic advancements over many years, MM remains largely incurable. These hyperproliferative differentiated B-lymphocytes can produce various types of immunoglobulins (Ig), with IgG and I...

 Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of clonal plasma cells in the bone marrow, which secrete significant quantities of non-functional proteins and immunoglobulins. Despite notable therapeutic advancements over many years, MM remains largely incurable. These hyperproliferative differentiated B-lymphocytes can produce various types of immunoglobulins (Ig), with IgG and IgA being the most common and IgD to a lesser extent. Typically, these abnormal plasma cells primarily grow within the bone marrow, with only a small fraction of patients initially showing extramedullary disease. Most patients experience relapses during treatment, progress to a refractory state, and cease to respond to therapy within 60 days of their last treatment: a grim prognosis and a high likelihood of relapse mark this. Additionally, with each subsequent relapse, patients endure progressively shorter periods of progression-free survival (PFS). For ins...

 Multiple myeloma is characterized by a monoclonal proliferation of plasma cells, resulting in monoclonal antibodies and end-organ damage. This can damage bone marrow, resulting in cytopenia, frail, brittle bones, or renal failure. The accumulation of the monoclonal antibody, Bence–Jones proteins, can precipitate in the urine resulting in kidney damage (usually type 2 renal tubular acidosis) and renal failure, which can be seen in two-thirds of MM cases. ·        An estimated 160,000 cases of Multiple myeloma were diagnosed globally, accounting for around 1% of all cancer-diagnosed cases. Approximately 90,000 of those cases were male, and 70,000 were female, which equals an age-standardized incidence of 2.1/100,000 and 1.4/100,000, respectively. ·        Approximately 59,000 of those deaths were male, and 47,000 were female, equalling age-standardized mortality of 1.3/100,000 and 0.9/100,000, respectively. Thelansis’...